Global Pharma News

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

by PRN

argenx to regain global rights to cusatuzumab

U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft

Daiichi Sankyo Submits Application for Additional Indication of Mirogabalin in Japan

Home Category Global Pharma News

Global Pharma News

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy

by PRN

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria

Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

Patritumab Deruxtecan Data Demonstrates Tumor Response Across Multiple Resistance Mechanisms

by PRN

New data from patritumab deruxtecan demonstrated preliminary evidence of clinically meaningful and durable tumor response in...

FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder

by PRN

U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen...

Novartis’s tislelizumab met primary endpoint in Phase III trial of esophageal cancer

by PRN

Novartis's Phase III trial shows anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy

$Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation$

Kite’s Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

by PRN

Kite, a Gilead Company announced results from Phase 1/2 study for its chimeric antigen receptor T-cell...

Gilead’s Trodelvy®Demonstrates Superior Outcomes in Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 Study

by PRN

Gilead Sciences, Inc. announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy)

FDA approves drug to treat smallpox

by PRN

The U.S. Food and Drug Administration approved Tembexa (brincidofovir) to treat smallpox. Although the World Health...

Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US

by PRN

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand...

Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years

AstraZeneca’s Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer

by PRN

Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful...

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma

by PRN